CN117083063A - 新型吸入剂 - Google Patents

新型吸入剂 Download PDF

Info

Publication number
CN117083063A
CN117083063A CN202180035149.1A CN202180035149A CN117083063A CN 117083063 A CN117083063 A CN 117083063A CN 202180035149 A CN202180035149 A CN 202180035149A CN 117083063 A CN117083063 A CN 117083063A
Authority
CN
China
Prior art keywords
cepharanthine
inhalation
inhalant
powder
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035149.1A
Other languages
English (en)
Chinese (zh)
Inventor
奥村睦男
村上诚一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of CN117083063A publication Critical patent/CN117083063A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180035149.1A 2020-05-14 2021-05-14 新型吸入剂 Pending CN117083063A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020085471 2020-05-14
JP2020-085471 2020-05-14
PCT/JP2021/018328 WO2021230340A1 (ja) 2020-05-14 2021-05-14 新規吸入剤

Publications (1)

Publication Number Publication Date
CN117083063A true CN117083063A (zh) 2023-11-17

Family

ID=78524492

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035149.1A Pending CN117083063A (zh) 2020-05-14 2021-05-14 新型吸入剂

Country Status (8)

Country Link
US (1) US20230338365A1 (https=)
EP (1) EP4151211A1 (https=)
JP (1) JPWO2021230340A1 (https=)
KR (1) KR20230011282A (https=)
CN (1) CN117083063A (https=)
AU (1) AU2021270426A1 (https=)
PH (1) PH12022553084A1 (https=)
WO (1) WO2021230340A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
JP2024178477A (ja) * 2021-11-04 2024-12-25 興和株式会社 カプセル剤
JP2024178478A (ja) * 2021-11-04 2024-12-25 興和株式会社 医薬品
CN118555958A (zh) * 2021-11-17 2024-08-27 国立感染症研究所所长代表的日本国 含有来自金线吊乌龟的生物碱的制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1452967A (zh) * 2003-06-19 2003-11-05 广州暨南生物医药研究开发基地有限公司 千金藤素在制备抗sars病毒药物中的应用
CN1771953A (zh) * 2005-11-01 2006-05-17 袁继民 一种含有千金藤素的药物
CN101090711A (zh) * 2004-10-29 2007-12-19 哈佛学院校长同事会 治疗肺部感染的颗粒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
CN110151691A (zh) * 2019-06-19 2019-08-23 宁夏医科大学 一种千金藤素纳米混悬液及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1452967A (zh) * 2003-06-19 2003-11-05 广州暨南生物医药研究开发基地有限公司 千金藤素在制备抗sars病毒药物中的应用
CN101090711A (zh) * 2004-10-29 2007-12-19 哈佛学院校长同事会 治疗肺部感染的颗粒
CN1771953A (zh) * 2005-11-01 2006-05-17 袁继民 一种含有千金藤素的药物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
F. SHIGERU ET AL.: ""Nebulization Treatment of Chronic Sinusitis"", 《JIBI INKOKA TEMBO.》, vol. 23, no. 4, 31 December 1980 (1980-12-31), pages 28 - 34 *
H OHASHI，ET AL.: ""Multidrug Treatment with Nelfinavir and Cepharanthine Against COVID-19"", 《BIORXIV.》, 5 April 2020 (2020-04-05), pages 1 - 16 *
王伟主编: "《肿瘤药剂学》", 30 November 2016, 江苏凤凰科学技术出版社, pages: 185 *
王倩等: ""千金藤干粉吸入剂治疗矽肺作用的研究"", 《职业与健康》, vol. 21, no. 11, 30 November 2005 (2005-11-30), pages 1723 *

Also Published As

Publication number Publication date
WO2021230340A1 (ja) 2021-11-18
JPWO2021230340A1 (https=) 2021-11-18
AU2021270426A1 (en) 2022-12-08
US20230338365A1 (en) 2023-10-26
EP4151211A1 (en) 2023-03-22
KR20230011282A (ko) 2023-01-20
PH12022553084A1 (en) 2024-03-25

Similar Documents

Publication Publication Date Title
CN117083063A (zh) 新型吸入剂
AU2002244211B2 (en) Aerosol Compositions Containing Formoterol for Delivery to the Lungs via Nebulization
EP2916826B1 (en) Ultra low density pulmonary powders
TWI758617B (zh) 包含格隆銨鹽及茚達特羅鹽的氣霧劑藥物組合物、其製備方法與用途
EP2329861A1 (en) Pharmaceutical products and compositions comprising formoterol, budesonide and ipratropium
HRP20000666A2 (en) Pulmonary and nasal delivery of raloxifene
AU2002244211A1 (en) Aerosol Compositions Containing Formoterol for Delivery to the Lungs via Nebulization
RS56848B1 (sr) Kombinacije antagonista muskarinskog receptora i agonista beta-2 adrenoreceptora
WO2011145109A1 (en) Dry powder inhalation composition
EP3932400B1 (en) Peramivir solution type inhalant and preparation method therefor
US20100269825A1 (en) Inhalation particles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1h)-quinolinone and a corticosteroid
CN117205186B (zh) 一种雷芬那辛吸入喷雾剂及其制备方法
EP2957553A1 (en) Pharmaceutical formulations of vilanterol
JP2024049405A (ja) 新規吸入剤
EP1494648B1 (en) Powder formulations suitable for inhalation
EP1169065A1 (en) Formulations for detecting asthma
JP2024125434A (ja) 新規吸入剤
WO2007046113A2 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
CN116196298A (zh) 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用
EP2826479A1 (en) Ameliorating agent for chronic obstructive pulmonary disease
DE60202299T2 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
WO2023068287A1 (ja) 新規医薬
EP1660046A1 (de) Pulverinhalativum enthaltend den cgrp-antagonisten 1-(n2-(3,5-dibrom-n-((4-(3,4-dihydro-2(1h)-oxochinazolin-3-yl)-1-piperidinyl)carbonyl)-d-tyrosyl)-l-lysyl)-4-(4-pyridinyl)-piperazin
EP0465841A2 (de) Schnellwirksame Inhalationsarzneiformen von Diuretika
US20120097160A1 (en) Agglomerate formulations including active pharmaceutical agents with targeted particle sizes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination